News | November 01, 2024
Merck and Moderna initiate Phase 3 trial evaluating adjuvant V940 in combination with Keytruda
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
The workshop aimed to equip medicos with the necessary skills & knowledge to leverage AI's transformative power
Potential to optimize and build on the synergies in commercial operations, distribution, manufacturing, supply chain etc.
Silica is a proven and highly effective anti-caking agent that has been used for decades
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
Subscribe To Our Newsletter & Stay Updated
